This phase I trial is evaluating the safety and effectiveness of a new oral drug (TG-1701) for patients with B-cell malignancies that have not responded or gotten worse with prior treatments.
This trial is treating patients with B-cell malignancies.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1 Pharmacokinetic and Pharmacodynamic Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
TG Therapeutics, Inc.
This is a non-randomised trial, in which patients will be allocated to receive an oral dose of TG-1701 alone OR in combination with oral Umbralisib and Ublituximab at a fixed IV infusion on specific Days, followed by maintenance infusions.
Recruiting Hospitals Read More